ATNM קצב צמיחת רווח למניה בשנה הנוכחית Actinium Corp

סמלים רשמיים של חברת actiniumpharma.com (ATNM)

Actinium Pharmaceuticals (ATNM) is growing its capital through partnerships with pharma behemoths to bring radioimmunotherapy to market. Annual EPS growth demonstrates profit dynamics, where 115.80 indicates the current level. However, geopolitical risks are undermining drug logistics, and an excessive bet on final trials creates a dependency on a single regulatory decision.

ATNM - צמיחת רווחים בשנה הנוכחית Actinium Pharmaceuticals, Inc. בטווח 04.07.2022 - 17.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Actinium Pharmaceuticals (ATNM)

- שווי מניות ותחזית קונצנזוס למחירים:
הערכת שווי פונדמנטלית:ATNM - Actinium Corp
מוצר עיקרי של Actinium Corp

Actinium Pharmaceuticals operates in the high-risk radiopharmaceutical sector. The year-over-year (YoY) net income per share change ratio reflects EPS dynamics relative to the same period last year. Growth in this metric signals the effective capitalization of scientific research. For Actinium Pharmaceuticals (ATNM), such a metric confirms financial stability while adhering to strict bioethical and radiation ESG standards. A positive trend justifies the company's investment attractiveness.